Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

NCT01170962 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

512

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus

Interventions

DRUG: BMS-790052
DRUG: BMS-790052
DRUG: Placebo
DRUG: peginterferon alfa-2a
DRUG: ribavirin

Sponsor

Bristol-Myers Squibb